WHEN MTX IS NO LONGER AN OPTION FOR YOUR DMARD-IR RA PATIENTS, CONSIDER ACTEMRA
Contact a rep at ActemraHCP.com for more information
ACTEMRA DELIVERED RAPID RESPONSE AT WEEK 2 AS A SINGLE AGENT AMBITION: ACR20 Responses Over Time (24 Weeks)1,2 100 ACTEMRA 8 mg/kg IV (every 4 weeks)* (n=286) MTX (n=284)
80
P<0.001
70
ACTEMRA MONOTHERAPY: RAPID RESPONSE AT WEEK 2
Patients (%)
60
53 40
20
AMBITION: Pivotal, randomized, double-blind, Phase III clinical study in MTX-naïve/-free† patients with moderate to severe RA. The primary endpoint was ACR20 response at Week 24. Patients were treated with ACTEMRA 8 mg/kg IV (every 4 weeks)* or an escalating dose of MTX. MTX dose was initiated at 7.5 mg/week and increased to a maximum dose of 20 mg/week within 8 weeks. The treatment period was 24 weeks. *The recommended starting dose for ACTEMRA IV is 4 mg/kg followed by an increase to 8 mg/kg based on clinical response. † ACTEMRA is not indicated for the treatment of MTX-naïve patients with rheumatoid arthritis (RA). ACTEMRA is indicated for the treatment of adult patients with moderately to severely active RA who have had an inadequate response to one or more DMARDs.
Select Important Safety Information Primary endpoint: ACR20 response at Week 24
0 BL
2
4
8
12
16
20
24
Contraindication ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.
Time (weeks)
MTX=methotrexate.
Please see following pages for full Important Safety Information and brief summary of Prescribing Information.